ImmunityBio Secures $80 Million in Direct Offering with Institutional Investors
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered...